Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 5:16 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1729–1752 of 2,906 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Capsules Clear all
Completed Phase 4 Interventional Results available

Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension

NCT00931710
View directory record Official record
Conditions
Stage 2 Systolic Hypertension
Interventions
valsartan, amlodipine, HCTZ, Losartan, HCTZ followed by valsartan, amlodipine, HCTZ
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 7, 2011 · Synced Nov 2, 2026, 5:16 PM EST
Completed Phase 3 Interventional Results available

A Trial Evaluating the Efficacy and Safety of HLD200 in Children With ADHD

NCT02255513
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
HLD200, Placebo
Drug
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Other
Eligibility
6 Years to 12 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
4
States / cities
Newport Beach, California • Marshfield, Massachusetts • Las Vegas, Nevada + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Nov 2, 2026, 5:16 PM EST
Completed Phase 2 Interventional Results available

Green Tea or Polyphenon E in Preventing Lung Cancer in Former Smokers With Chronic Obstructive Pulmonary Disease

NCT00363805
View directory record Official record
Conditions
Lung Cancer Prevention
Interventions
green tea, Polyphenon E, placebo
Dietary Supplement · Drug · Other
Lead sponsor
Sherry Chow
Other
Eligibility
40 Years to 80 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
3
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 28, 2013 · Synced Nov 2, 2026, 5:16 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Trial for Alcohol Use Disorder and Post Traumatic Stress Disorder (PTSD)

NCT02966873
View directory record Official record
Conditions
Post Traumatic Stress Disorder (PTSD), Addiction, Alcohol Abuse
Interventions
N-Acetylcysteine (NAC) Treatment, Cognitive Behavioral Therapy (CBT), Inactive Placebo Oral Capsule, Functional magnetic resonance imaging (fMRI), Proton magnetic resonance spectroscopy (MRS) Imaging
Drug · Behavioral · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
182 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
2
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Nov 2, 2026, 5:16 PM EST
Terminated Phase 4 Interventional Results available

Thiazolidinedione Intervention With Vitamin D Evaluation

NCT00879970
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
pioglitazone, rosiglitazone, placebo, Vitamin D, Placebo
Drug · Dietary Supplement
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
1,332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
23
States / cities
Long Beach, California • Los Angeles, California • Northridge, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Nov 2, 2026, 5:16 PM EST
Terminated No phase listed Observational

Pain Study to See if Ultram ER Will Provide Relief to Subjects Whose Pain is Not Well Controlled by Narcotics

NCT00505531
View directory record Official record
Conditions
Chronic Pain
Interventions
Tramadol Extended Release Oral Capsule, Benadryl
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Nov 2, 2026, 5:16 PM EST
Completed Phase 2 Interventional Results available

A Clinical Study of Mesdopetam in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia

NCT04435431
View directory record Official record
Conditions
Parkinson Disease
Interventions
Mesdopetam, Placebo
Drug
Lead sponsor
Integrative Research Laboratories AB
Industry
Eligibility
30 Years to 79 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
14
States / cities
Scottsdale, Arizona • Long Beach, California • Palo Alto, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Nov 2, 2026, 5:16 PM EST
Terminated Phase 3 Interventional Results available

Safety and Efficacy of Vanoxerine for the Conversion of Subjects With Recent Onset Atrial Fibrillation or Flutter to Normal Sinus Rhythm

NCT02454283
View directory record Official record
Conditions
Atrial Fibrillation or Flutter
Interventions
Vanoxerine HCl, Placebo
Drug
Lead sponsor
Laguna Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
4
States / cities
Littleton, Colorado • Washington D.C., District of Columbia • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Nov 2, 2026, 5:16 PM EST
Completed Phase 1 Interventional

Study of the Safety & PK of INX-08189 in Chronically-infected HCV, Treatment-naïve Subjects

NCT01250366
View directory record Official record
Conditions
HCV (Genotype 1)
Interventions
INX-08189, Placebo matching with INX-08189, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Los Angeles, California • Plymouth, Minnesota • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2012 · Synced Nov 2, 2026, 5:16 PM EST
Completed Not applicable Interventional Results available

Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia

NCT01338298
View directory record Official record
Conditions
Hyperprolactinemia
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 27, 2019 · Synced Nov 2, 2026, 5:16 PM EST
Completed Phase 3 Interventional Results available

Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy

NCT03470545
View directory record Official record
Conditions
Obstructive Hypertrophic Cardiomyopathy
Interventions
mavacamten, Placebo
Drug
Lead sponsor
MyoKardia, Inc.
Industry
Eligibility
18 Years and older
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
29
States / cities
Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Nov 2, 2026, 5:16 PM EST
Active, not recruiting Phase 2Phase 3 Interventional

A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy

NCT05707377
View directory record Official record
Conditions
Primary Membranous Nephropathy
Interventions
Zanubrutinib, Tacrolimus
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years to 75 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
Granada Hills, California • Palo Alto, California • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Nov 2, 2026, 5:16 PM EST
Completed Phase 2 Interventional Results available

Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies

NCT03888222
View directory record Official record
Conditions
Dementia With Lewy Bodies
Interventions
Placebo Oral Tablet, Bosutinib Oral Tablet
Drug
Lead sponsor
Georgetown University
Other
Eligibility
25 Years to 90 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Nov 2, 2026, 5:16 PM EST
Enrolling by invitation Early Phase 1 Interventional

Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder

NCT04509102
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Adderall-XR, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Nov 2, 2026, 5:16 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Rapid Response of Stem Cells and Immune Cells for Efficacy

NCT07127705
View directory record Official record
Conditions
Stem Cell Surveillance
Interventions
Placebo, Chaga Mushroom, Ginseng extract, Olive extract, Potassium Hydrogen Glucarate
Dietary Supplement
Lead sponsor
Natural Immune Systems Inc
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Klamath Falls, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Nov 2, 2026, 5:16 PM EST
Completed Early Phase 1 Interventional Results available

Psilocybin Cancer Anxiety Study

NCT00957359
View directory record Official record
Conditions
Cancer
Interventions
Psilocybin, Niacin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 76 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Nov 2, 2026, 5:16 PM EST
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

NCT03131453
View directory record Official record
Conditions
Alzheimers Disease
Interventions
CNP520 50mg, CNP520 15mg, Matching placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
60 Years to 75 Years
Enrollment
1,145 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
95
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Nov 2, 2026, 5:16 PM EST
Completed Phase 4 Interventional Results available

A Phase IV Safety and Efficacy Study of VI-0521 in Adolescents With Obesity

NCT03922945
View directory record Official record
Conditions
Adolescent Obesity, Obesity in Adolescence, Adolescent Overweight
Interventions
VI-0521 oral capsule, Placebo oral capsule, Lifestyle Modification
Drug · Behavioral
Lead sponsor
VIVUS LLC
Industry
Eligibility
12 Years to 16 Years
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Norman, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 10, 2022 · Synced Nov 2, 2026, 5:16 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Multiple Ascending Dose Study of TMP-301 in Healthy Subjects

NCT06025396
View directory record Official record
Conditions
Cocaine Use Disorder, Substance Use Disorders, Healthy Volunteers
Interventions
Cohort 1 - TMP-301, Placebo, Cohort 2 - TMP-301, Cohort 3 - TMP-301, Cohort 4 - TMP-301
Drug
Lead sponsor
Tempero Bio, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Nov 2, 2026, 5:16 PM EST
Completed Phase 3 Interventional Results available

Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty

NCT00657150
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Enoxaparin, Dabigatran etexilate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2,055 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
10
States / cities
La Jolla, California • Aurora, Colorado • Englewood, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Nov 2, 2026, 5:16 PM EST
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

The Role of Acetazolamide in Mitigating Inflammation and Innate Immune Activation at High Altitude

NCT07517068
View directory record Official record
Conditions
Hypoxemia, Acute Mountain Sickness (AMS), Inflammation, Immune Response
Interventions
ACETAZOLAMIDE oral capsule, Placebo Arm
Drug · Device
Lead sponsor
University of California, Riverside
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Riverside, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Nov 2, 2026, 5:16 PM EST
Completed Phase 4 Interventional Results available

Adolescent Fibromyalgia Study

NCT01020474
View directory record Official record
Conditions
Fibromyalgia
Interventions
placebo, pregabalin (Lyrica)
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
30
States / cities
Los Angeles, California • Santa Ana, California • Delray Beach, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Nov 2, 2026, 5:16 PM EST
Completed Phase 2 Interventional Results available

Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1)

NCT01888874
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
GLPG0634, Placebo
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
18 Years and older
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
28
States / cities
Huntsville, Alabama • Gilbert, Arizona • Phoenix, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Nov 2, 2026, 5:16 PM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder

NCT01972074
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Memantine, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
8 Years to 17 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Nov 2, 2026, 5:16 PM EST